Huvepharma extends deadline after getting ratings
![Drugs Pharma](https://assets.euromoneydigital.com/dims4/default/58c3831/2147483647/strip/true/crop/175x233+0+0/resize/840x1118!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2F84%2F8d%2F75106f640437c83bbda0c2f26f97%2Fdrugs-generic-pharma.jpg)
Bankers now hope to complete a €275m acquisition loan for Bulgarian drugs firm Huvepharma this week after extending the deadline to wait for Moody's and Standard & Poor's to provide ratings.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: